Clinical trial
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of…
NCT00419419 · MediQuest Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00419419 |
|---|---|
| Title | Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon |
| Official title | Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon |
| Lead sponsor | MediQuest Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Raynaud's Disease, Scleroderma, Autoimmune Diseases |
| Intervention type | Drug |
| Interventions | Topical AmphiMatrix with nitroglycerin (MQX-503) |
| Enrollment | 80 |
| Start date | Dec 1, 2006 |
| First posted | Jan 8, 2007 |
| Last update posted | May 30, 2007 |
| Countries | Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: